---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-026247"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:13:05.652350+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix board reconstituted; four directors retire, five new directors elected, LTIP share pool expanded

## Summary
- Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.
- Stockholders elected Doron Besser, David Johnson, Zeev Rotstein, Nino Pionati, Alison Geiger Burgett as directors for one-year terms.
- First Amendment to 2024 Long-Term Incentive Plan approved; shares reserved increased by 1,200,000 to 1,205,454 shares.
- Share issuance proposal under Nasdaq Rule 5635(d) approved, covering convertible preferred stock and warrants from July 2025 private placement.
- Kost Forer Gabbay & Kasierer (EY) ratified as independent auditor for FY 2025.

## SEC filing metadata
- accession: 0001493152-25-026247
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315225026247/0001493152-25-026247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315225026247/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-026247
- JSON: https://secwatch.observer/filing/0001493152-25-026247.json
- Plain text: https://secwatch.observer/filing/0001493152-25-026247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.